Share price · TAK
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when TAK's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 30 Oct 2026+4.5%
- 17 Jul 2026+2.5%
- 2 Jul 2026+5.1%
Nothing announced by TAK that day or the session before.
- 1 Jun 2026-4.8%
- 22 Apr 2026-2.7%
Nothing announced by TAK that day or the session before.
- 10 Feb 2026+2.1%
- 29 Jan 2026+2.9%
- 23 Jan 2026+2.2%
Nothing announced by TAK that day or the session before.
- 8 Jan 2026+3.0%
Nothing announced by TAK that day or the session before.
- 23 Dec 2025+2.4%
Nothing announced by TAK that day or the session before.
Share of unusual movement by asset
For each asset, the share of TAK's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
Assets
(42 total)
| Target & Modality | |||
|---|---|---|---|
Alogliptin(Nesina) | Approved | DPP-4Small molecule | Type 2 Diabetes |
| Approved | ProteasomeSmall molecule | Multiple MyelomaMantle Cell Lymphoma | |
| Approved | Anti-CD30 antibody-drug conjugateAntibody–drug conjugate | Non-Small Cell Lung CancerDiffuse Large B-Cell LymphomaNon-Hodgkin LymphomaCutaneous T-Cell Lymphoma Large B-Cell Lymphoma, Peripheral T-Cell Lymphoma, High-Grade B-Cell Lymphoma | |
| Approved | ALKSmall molecule | Non-Small Cell Lung Cancer | |
| Approved | MET / VEGFR / AXL / RET (multi-kinase)Small molecule | Non-Small Cell Lung CancerRenal Cell CarcinomaHepatocellular CarcinomaProstate Cancer Clear Cell Renal Cell Carcinoma | |
| Approved | Myelin basic protein-mimetic immunomodulationPeptide | Multiple Sclerosis | |
Fruquintinib(Fruzaqla / Elunate) | Approved | VEGFR1/2/3Small molecule | Colorectal CancerRenal Cell CarcinomaEndometrial Cancer Metastatic Colorectal Cancer, Advanced Metastatic Colorectal Cancer |
| Approved | ProteasomeSmall molecule | Multiple Myeloma | |
maralixibat(Livmarli) | Approved | Ileal bile acid transporter (IBAT)Small molecule | Alagille Syndrome |
| Approved | AminosalicylateSmall molecule | Inflammatory Bowel Disease Ulcerative Colitis | |
| Approved | AminosalicylateSmall molecule | Inflammatory Bowel Disease Ulcerative Colitis | |
Mirvetuximab soravtansine(Elahere) | Approved | —Antibody–drug conjugate | Ovarian Cancer |
Oveporexton(Orzeyful) | Approved | Orexin-2 receptor (agonist)Small molecule | Narcolepsy |
Pioglitazone(Actos) | Approved | PPAR-gammaSmall molecule | Type 2 Diabetes |
Ponatinib(ICLUSIG) | Approved | BCR-ABL (including T315I)Small molecule | Chronic Myeloid LeukemiaAcute Lymphoblastic Leukemia |
Upcoming events
(72 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2026 (7)
November 2026 (4)
What to watch
What to watch
What to watch
December 2026 (3)
What to watch
2027 (20)
February 2027 (4)
March 2027 (2)
April 2027 (1)
What to watch
May 2027 (3)
June 2027 (1)
What to watch
July 2027 (3)
September 2027 (2)
October 2027 (1)
What to watch
November 2027 (1)
2028 (19)
February 2028 (3)
What to watch
What to watch
What to watch
March 2028 (2)
May 2028 (2)
June 2028 (2)
July 2028 (2)
August 2028 (1)
What to watch
September 2028 (3)
October 2028 (2)
November 2028 (1)
2029 (15)
January 2029 (5)
What to watch
What to watch
What to watch
What to watch
What to watch
April 2029 (1)
What to watch
May 2029 (2)
July 2029 (1)
What to watch
August 2029 (1)
What to watch
September 2029 (1)
What to watch
October 2029 (1)
What to watch
2030 (7)
January 2030 (1)
What to watch
February 2030 (1)
What to watch
March 2030 (1)
What to watch
April 2030 (1)
What to watch
May 2030 (1)
What to watch
August 2030 (2)
What to watch
2031 (1)
2033 (2)
2034 (1)
July 2034 (1)
What to watch
Regulatory and conference events
(19)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Coming up
Recent
The 12 most recent of 18 past events are shown.
Financial reports
Quarterly & interim (10)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-H1 | $15.2B | — | — | — | report ↗ |
For H1 FY2025 (ended September 30, 2025), Takeda reported revenue of $15,208.27M, down 2.8% YoY (¥2,219.5B, down 6.9% at actual exchange rates). Reported operating profit was ¥253.6B, down 27.7% YoY, and reported net profit was ¥112.4B, down 40.0% YoY. R&D spend and cash position were not disclosed.
Management updated full-year guidance: core revenue remains broadly flat at CER, while core operating profit and core EPS were revised from broadly flat to low-single-digit percentage declines. Reported full-year forecasts were revised to revenue of ¥4,500.0B, operating profit of ¥400.0B, net profit of ¥153.0B, EPS of ¥97, core EPS of ¥479, and adjusted free cash flow of ¥600.0-700.0B, with annual dividend unchanged at ¥200 per share. The company expects regulatory filings for rusfertide and oveporexton in H2 FY2025, Phase 3 results for zasocitinib, and highlighted a global strategic oncology partnership with Innovent Biologics. The outlook revision reflects FX impacts and impairment losses on the gamma delta T-cell therapy platform.
View 9 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q1 | $7.7B | — | — | — | report ↗ |
| 2025-H1 | $15.7B | — | — | — | report ↗ |
| 2025-Q1 | $7.8B | — | — | — | report ↗ |
| 2024-H1 | $14.9B | — | — | — | report ↗ |
| 2024-Q1 | $7.7B | — | — | — | report ↗ |
| 2023-H1 | $14.8B | — | — | — | report ↗ |
| 2023-Q1 | $7.5B | — | — | — | report ↗ |
| 2022-H1 | $16.3B | — | — | — | report ↗ |
| 2022-Q1 | $8.7B | — | — | — | report ↗ |
Annual history (10 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | $27.5B | $4.1B | — | — | report ↗ |
View 9 more years
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-9M | $22.1B | $3.1B | $4.2B | — | report ↗ |
| 2025-9M | $23.2B | — | — | — | report ↗ |
| 2024-FY | $29.4B | $5.0B | $3.0B | —$4.9B operating cash flow | report ↗ |
| 2024-9M | $21.7B | — | — | — | report ↗ |
| 2023-FY | $29.6B | $4.7B | $4.0B | —$7.2B operating cash flow | report ↗ |
| 2023-9M | $21.7B | — | — | — | report ↗ |
| 2022-FY | $31.7B | $4.7B | $7.0B | —$10.0B operating cash flow | report ↗ |
| 2022-9M | $23.7B | — | — | — | report ↗ |
| 2021-FY | $30.2B | $4.3B | $8.8B | —$9.6B operating cash flow | report ↗ |
Insider transactions
Open-market activity, trailing 12 months: 0 purchases ($0), 22 sales ($15.2M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-11-04 | Platford Giles Richard · President, IBU | Open-market sale | 55,617 | $20.90 | $1.2M | Form 4 |
| 2026-11-02 | Bitetti Teresa Marie · President, OBU | Open-market sale | 46,609 | $20.89 | $974K | Form 4 |
| 2026-09-14 | Duprey Lauren Rusckowski · Chief Transformation Officer | Open-market sale | 34,535 | $18.54 | $640K | Form 4 |
| 2026-09-02 | Plump Andrew Stewart · director, President, R&D | Open-market sale | 116,191 | $18.49 | $2.1M | Form 4 |
| 2026-08-19 | Plump Andrew Stewart · director, President, R&D | Open-market sale | 19,651 | $18.49 | $363K | Form 4 |
| 2026-08-18 | Greenway Nicola Deidre Petal · Chief Human Resources Officer | Open-market sale | 12,980 | $18.11 | $235K | Form 4 |
| 2026-08-11 | Shannon Elaine Mary · Pres., Global Supply & Quality | Open-market sale | 20,363 | $17.55 | $357K | Form 4 |
| 2026-08-10 | Greenway Nicola Deidre Petal · Chief Human Resources Officer | Open-market sale | 975 | $17.50 | $17K | Form 4 |
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 357 reporting institutions held 98.2M shares ($1.8B, 3.1% of shares outstanding).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | Capital Research Global Investors | 19,104,219 | $353.8M |
| 2 | FMR LLC | 7,117,486 | $131.8M |
| 3 | MORGAN STANLEY | 6,469,600 | $119.8M |
| 4 | ADAGE CAPITAL PARTNERS GP, L.L.C. | 6,424,984 | $119.0M |
| 5 | GOLDMAN SACHS GROUP INC | 5,618,728 | $104.1M |
| 6 | BRANDES INVESTMENT PARTNERS, LP | 4,430,642 | $82.1M |
| 7 | BlackRock, Inc. | 3,176,421 | $58.8M |
| 8 | ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | 3,116,311 | $57.7M |
| 9 | RENAISSANCE TECHNOLOGIES LLC | 2,989,100 | $55.4M |
| 10 | UBS Group AG | 2,740,229 | $50.7M |
| 11 | D. E. Shaw & Co., Inc. | 2,602,543 | $48.2M |
| 12 | FIRST TRUST ADVISORS LP | 1,971,074 | $36.5M |
| 13 | NORTHERN TRUST CORP | 1,961,038 | $36.3M |
| 14 | MANAGED ASSET PORTFOLIOS, LLC | 1,798,398 | $33.3M |
| 15 | ENVESTNET ASSET MANAGEMENT INC | 1,411,927 | $26.1M |